Okiljević Bogdan, Martić Nikola, Govedarica Srđan, Andrejić Višnjić Bojana, Bosanac Milana, Baljak Jovan, Pavlić Branimir, Milanović Isidora, Rašković Aleksandar
Department of Cardiac Surgery, Dedinje Cardiovascular Institute, 11000 Belgrade, Serbia.
Department of Pharmacology, Toxicology, and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia.
Pharmaceutics. 2024 Apr 9;16(4):520. doi: 10.3390/pharmaceutics16040520.
Silymarin, derived from , has been used in traditional medicine for various ailments. In this study, the cardioprotective and hepatoprotective effects of silymarin against paracetamol-induced oxidative stress were examined in 28 male Swiss Webster mice, divided into four groups and treated for 7 days (via the oral route) with (a) saline 1 mL/kg (control group), (b) saline 1 mL/kg + single dose of paracetamol 110 mg/kg on the 7th day; (c) silymarin 50 mg/kg; and (d) silymarin 50 mg/kg + single dose of paracetamol 110 mg/kg on the 7th day. In vitro and in vivo antioxidant activity together with liver enzyme activity were evaluated. Histopathological and immunohistochemical assessment was performed. Silymarin mitigated paracetamol-induced liver injury by reducing oxidative stress markers such as lipid peroxidation and restoring antioxidant enzyme activity. Silymarin treatment resulted in a significant decrease in liver enzyme levels. Reduced necrosis and inflammatory infiltrate in liver tissues of silymarin-treated groups were detected as well. Immunohistochemical analysis demonstrated reduced expression of inflammatory markers (COX2, iNOS) and oxidative stress marker (SOD2) in the liver tissues of the silymarin-treated groups. Similar trends were observed in cardiac tissue. These results suggest that silymarin exerts potent hepatoprotective and cardioprotective effects against paracetamol-induced oxidative stress, making it a promising therapeutic agent for liver and heart diseases associated with oxidative damage.
水飞蓟素源自[此处原文缺失具体来源]，已在传统医学中用于治疗各种疾病。在本研究中，对28只雄性瑞士韦伯斯特小鼠进行了实验，以检验水飞蓟素对扑热息痛诱导的氧化应激的心脏保护和肝脏保护作用。这些小鼠被分为四组，通过口服途径进行为期7天的治疗，具体如下：(a) 1 mL/kg生理盐水（对照组）；(b) 1 mL/kg生理盐水 + 第7天单剂量110 mg/kg扑热息痛；(c) 50 mg/kg水飞蓟素；(d) 50 mg/kg水飞蓟素 + 第7天单剂量110 mg/kg扑热息痛。评估了体外和体内的抗氧化活性以及肝酶活性，并进行了组织病理学和免疫组织化学评估。水飞蓟素通过降低脂质过氧化等氧化应激标志物并恢复抗氧化酶活性，减轻了扑热息痛诱导的肝损伤。水飞蓟素治疗使肝酶水平显著降低，同时在水飞蓟素治疗组的肝脏组织中检测到坏死和炎性浸润减少。免疫组织化学分析表明，水飞蓟素治疗组肝脏组织中炎症标志物（COX2、iNOS）和氧化应激标志物（SOD2）的表达降低。在心脏组织中也观察到了类似趋势。这些结果表明，水飞蓟素对扑热息痛诱导的氧化应激具有强大的肝脏保护和心脏保护作用，使其成为治疗与氧化损伤相关的肝脏和心脏疾病的有前景的治疗药物。
